Ambulatory Care 

Originally presented at HOPA's 13th Annual Conference, March 2017.

Matters Close to the Heart: Cardio-Oncology in Breast Cancer 

Therapeutic advancements over recent decades have led to a growing number of breast cancer survivors. However, these successes have been overshadowed by the unintended, and often devastating, cardiac outcomes affecting survivors of breast cancer. Anthracyclines and trastuzumab represent the agents responsible for left ventricular dysfunction and heart failure. In general, healthcare providers are operating in a reactive rather than a proactive manner when monitoring for cardiotoxicity. Ideally, detecting cardiac damage before it results in decline in ejection fraction may lead to better cardiac outcomes. Emerging strategies in prevention and monitoring will be highlighted.

Learning Objectives

  • Review the epidemiology of cardiotoxicity in breast cancer patients.
  • Discuss emerging prevention and monitoring strategies for breast cancer patients receiving cardiotoxic agents.


Sandra Cuellar, PharmD BCOP

Sandra Cuellar is a clinical assistant professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy. She is the clinical pharmacist in the cancer center and director of the oncology specialty residency program. She is an editor at large for Journal of Hematology Oncology Pharmacy and is involved in research, consulting, and publications in the field of hematology/oncology. She is a member of the American Society of Health-System Pharmacists educational steering committee and chair of the 2016–2017 HOPA BCOP Recertification Committee.

Activity type

Patient Management & Therapeutics

Implementation of Advanced Pharmacy Services into a Multiple Myeloma Ambulatory Clinic

Many barriers exist to providing comprehensive care to patients with multiple myeloma. With the approval of multiple new agents, therapeutic decision making and the regimens patients are required to adhere to have become increasingly complex. In this session, experiences with the incorporation of clinical pharmacists into direct patient care within an ambulatory multiple myeloma clinic will be shared. The role of pharmacy specialists regarding support for therapeutic recommendations and monitoring, therapy adherence, compliance with Risk Evaluation and Mitigation Strategies (REMS), supportive care considerations, and financial and case management will also be reviewed. Finally, the outcomes resulting from the implementation of this service will be discussed.

Learning Objectives

  • Discuss the need for the integration of specialized pharmacists into an ambulatory multiple myeloma clinic and the potential advanced services that can be provided.
  • Outline the steps necessary to implement a feasible, pharmacist-involved service into the multiple myeloma clinic setting.
  • Identify important barriers and other considerations for pharmacists seeking to implement advanced pharmacy services into a multiple myeloma clinic.


Scott Wirth, PharmD BCOP

Scott Wirth is a clinical hematology/oncology pharmacist at the University of Illinois at Chicago (UIC) Cancer Center and a clinical assistant professor at the UIC College of Pharmacy. In these positions he advises on therapeutic decision making, provides patient education, performs clinical research, serves as a preceptor to students and PGY-1 and PGY-2 residents, and is involved in multiple quality initiatives. He received his PharmD degree from the UIC College of Pharmacy and completed PGY-1 and PGY-2 hematology/oncology programs at the University of Kentucky.

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.

This activity has been approved for .1 CEU

This course is also included as part of the Best of AC2017 Bundle product.

Release Date: August 31, 2017

Expiration Date: March 29, 2020

Member: $25

Non-Member: $35

Purchase Now